Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.87 USD
-0.01 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.87 0.00 (-0.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ADAP 0.87 -0.01(-0.84%)
Will ADAP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADAP
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
Adaptimmune (ADAP) Down on End of Collaboration With Roche
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Other News for ADAP
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
Biotech Alert: Searches spiking for these stocks today
Hold Rating on Adaptimmune Amid Commercialization and Financial Uncertainties
Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)